Cognition Therapeutics, Inc. (CGTX)

NCM – Real Time Price. Currency in USD

1.18

0.00 (0.00%)

At close: May 12, 2026, 4:00 PM EDT

1.20

+0.02 (1.58%)

After-hours: May 12, 2026, 6:57 PM EDT

07.05.2026

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

07.04.2026

Cognition Therapeutics to Present at Needham Virtual Healthcare Conference

PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi intends to present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13th at 3:00 p.m. Eastern Time. During her presentation, Ms. Ricciardi will provide an update on progress of the Company's development programs for Alzheimer's disease and dementia with Lewy bodies (DLB).

31.03.2026

Cognition Therapeutics CEO Issues Letter to Shareholders

Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders, has published CEO Lisa Ricciardi's Letter to Shareholders.

26.03.2026

Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript

26.03.2026

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

-Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 - - Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y.

23.03.2026

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), plans to release financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 26, 2026 before the market open.

17.03.2026

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study (NCT05225415) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the AD/PD™ 2026 Alzheimer's & Parkinson's Diseases Conference. The conference is being conducted March 17-21, 2026 in Copenhagen, Denmark. The analysis focuses on Zervimesine's treatment effects on the behavioral and psychiatric symptoms most commonly associated with DLB.

Videos

No Data

There is no data to display

Press releases

07.05.2026

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

31.03.2026

Cognition Therapeutics CEO Issues Letter to Shareholders

26.03.2026

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

-Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 - - Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y.

17.03.2026

Cognition Therapeutics, Inc. (CGTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cognition Therapeutics, Inc. (CGTX)

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

Cognition Therapeutics to Present at Needham Virtual Healthcare Conference

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

Videos

No Data

Press releases

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

Cognition Therapeutics to Present at Needham Virtual Healthcare Conference

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

Videos

No Data

Press releases

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

Search stocks

Cognition Therapeutics, Inc. (CGTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cognition Therapeutics, Inc. (CGTX)

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

Cognition Therapeutics to Present at Needham Virtual Healthcare Conference

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

Videos

No Data

Press releases

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

Cognition Therapeutics to Present at Needham Virtual Healthcare Conference

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

Videos

No Data

Press releases

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026